Thanks to weight loss medications, indulging in treats while shedding pounds is becoming a reality. Verdiva, a biotech startup based in London, has recently come out of stealth mode with an impressive $410 million funding round dedicated to developing new drugs to combat the obesity crisis. This marks one of the largest venture capital investments in European biotech history, highlighting strong investor interest in the rapidly growing weight loss sector.
Verdiva aims to compete with industry leaders Novo Nordisk and Eli Lilly, who produce the widely-used weight loss drugs Ozempic and Wegovy. The company is focused on providing oral medications that are less invasive than current injectable options. Its leading product is an oral GLP-1 formulation designed to suppress appetite…
